Studies gallbladder cancer and gallstones to find ways to predict and detect it
Observes people with gallstones or gallbladder cancer, collecting blood, saliva, urine, bile and stool samples.
Plain-language title generated from the registry record
Registry title: EULAT Eradicate GBC
Key facts
- Where
- Salta and San Salvador de Jujuy, ArgentinaSee the 3 sites
Where in Argentina
- Hospital Papa FranciscoSalta, ArgentinaTaking people
- Sanatorio el CarmenSalta, ArgentinaTaking people
- Hospital Pablo SoriaSan Salvador de Jujuy, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Paul Strauss
- Trial code
- NCT06192719
- Record updated
- 18 February 2026
- Original description
Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC).Read full original descriptionShow less
Establishment and Exploitation of a European-Latin American Research Consortium Towards Eradication of Preventable Gallbladder Cancer - EULAT Eradicate GBC
Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC).
Currently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker available to date to accurately predict risk and diagnose the disease early. The only curative treatment for GBC remains surgery with complete resection of tumors in early stages.
Given the aggressiveness of GBC and the very limited therapeutic options, as well as the possibility of preventing GBC by cholecystectomy during the 10 to 20 years required for the development of gallbladder tumors, it is imperative to develop effective and efficient prevention strategies based on a prioritization of interventions according to environmental and genetic-molecular risk factors.
The investigators aim to identify epidemiological factors linked to the development of GBC, and to identify, validate and functionally characterize genetic-molecular markers in blood, saliva, urine, bile and stool that allow risk prediction, early diagnosis and precision treatment of incidental tumors.
Inclusion: Cohort A. Patients with gallbladder cancer or dysplasia, both before and after the start of their anticancer treatment; Cohort B. Patients with cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited); Diagnosis confirmed in accordance with standard protocols of the participating hospitals; Men and women aged 18 or over.
Exclusion: Any medical condition that present an unreasonable risk to the participant; Any psychiatric condition that interferes with understanding informed consent.